ICER Lowers Recommended Price For COVID Drug Remdesivir

By Ariel Cohen / November 11, 2020 at 5:55 PM
The Institute for Clinical and Economic Review, which analyzes drug prices, lowered its recommended price for Gilead’s remdesivir after accounting for results from the World Health Organization-funded Solidarity trial. The antiviral did not reduce the death rate among COVID-19 patients in the Solidarity trial. In the United States, remdesivir’s price is currently capped at $3,120 per treatment course, even though Gilead set a uniform price for all developed countries that is $780 lower than that. This price was set in...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.